Drug Discovery and Proof of Concept 5

Vol 8, No 3 - Drug Discovery and Proof of Concept

Past issues

Contributors

How to publish

Contributions and comments

Home

Alert

To print this page in good conditions, please select the "Landscape" mode of your printer.

| Select and print |

C o n t e n t s Editorial Jean-Paul Macher In this issue Pierre Schulz State of the Art Expression profiling of drug response—from genes to pathways Ralf Herwig, Hans Lehrach (Germany) Pharmacological Aspects New directions for drug discovery Michael Spedding (France) Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled? Bryan L.Roth (USA) Membrane transporter proteins: a challenge for CNS drug development François Girardin (Switzerland) Experimental animal models for the simulation of depression and anxiety Eberhard Fuchs, Gabriele Flügge (Germany)

Clinical Research

The role of serendipity in drug discovery Thomas A. Ban (USA) Surrogate outcomes in neurology, psychiatry, and psychopharmacology Luc Staner (France) Free Paper Functional genomics in postmortem human brain: abnormalities in a DISC1 molecular pathway in schizophrenia Barbara K. Lipska, Shruti N. Mitkus, Shiny V. Mathew, Robert Fatula, Thomas M. Hyde, Daniel R. Weinberger, Joel E. Kleinman (USA) ISSUE COORDINATED BY: Pierre Schulz